Abstract WP153: Depressive Symptom Trajectories Are Associated With Blood Pressure Reduction Among Stroke Survivors

Stroke ◽  
2018 ◽  
Vol 49 (Suppl_1) ◽  
Author(s):  
Emily Goldmann ◽  
Bernadette Boden-Albala
Keyword(s):  
Blood Pressure ◽  
Depressive Symptom ◽  
Blood Pressure Reduction ◽  
Stroke Survivors ◽  
Pressure Reduction ◽  
Symptom Trajectories

Improvement of Insulin Sensitivity Contributes to Blood Pressure Reduction After Weight Loss in Hypertensive Subjects With Obesity

Hypertension ◽  
1996 ◽  
Vol 27 (5) ◽  
pp. 1180-1186 ◽  
Author(s):  
Toshio Ikeda ◽  
Tomoko Gomi ◽  
Nobuhito Hirawa ◽  
Jun Sakurai ◽  
Nori Yoshikawa
Keyword(s):  
Blood Pressure ◽  
Weight Loss ◽  
Insulin Sensitivity ◽  
Blood Pressure Reduction ◽  
Pressure Reduction

scholarly journals SGLT2 inhibitors and lower limb complications: an updated meta‐analysis

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Chu Lin ◽  
Xingyun Zhu ◽  
Xiaoling Cai ◽  
Wenjia Yang ◽  
Fang Lv ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Lower Limb ◽  
Blood Pressure Reduction ◽  
Random Effect Model ◽  
Diabetic Patients ◽  
Controlled Trials ◽  
Pressure Reduction ◽  
Effect Model ◽  
Meta Regression

Abstract Background To exam the associations between the use of sodium glucose co-transporter 2 inhibitor (SGLT2i) and the risk of lower limb complications, and to analyze the associated factors. Methods Pubmed, Medline, Embase, the Cochrane Center Register of Controlled Trials for Studies and Clinicaltrial.gov were searched from the inception to November 2020. Randomized controlled trials of SGLT2i conducted in population containing diabetic patients with reports of amputation, peripheral arterial disease (PAD) and diabetic foot (DF) events were included. Random-effect model, fixed-effect model and meta-regression analysis were accordingly used. Result The numbers of SGLT2i users versus non-SGLT2i users in the analyses of amputation, PAD and DF were 40,925/33,414, 36,446/28,685 and 31,907/25,570 respectively. Compared with non-SGLT2i users, the risks of amputation and PAD were slightly increased in patients with canagliflozin treatment (amputation: OR = 1.60, 95% CI 1.04 to 2.46; PAD: OR = 1.53, 95 % CI 1.14 to 2.05). Meta-regression analyses indicated that greater weight reduction in SGLT2i users was significantly associated with the increased risks of amputation (β = − 0.461, 95% CI − 0.726 to − 0.197), PAD (β = − 0.359, 95% CI − 0.545 to − 0.172) and DF (β = − 0.476, 95% CI − 0.836 to − 0.116). Lower baseline diastolic blood pressure (β = − 0.528, 95% CI − 0.852 to − 0.205), more systolic blood pressure reduction (β = − 0.207, 95% CI − 0.390 to − 0.023) and more diastolic blood pressure reduction (β = − 0.312, 95% CI − 0.610 to − 0.015) were significantly associated with the increased risks of amputation, PAD and DF respectively in patients with SGLT2i treatment. Conclusions The risks of amputation and PAD were slightly increased in patients with canagliflozin treatment. Reductions in body weight and blood pressure were associated with lower limb complications in patients with SGLT2i treatment.

scholarly journals Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors

2016 ◽  
Vol 17 (12) ◽  
pp. 1581-1583 ◽  
Author(s):  
T. D. Filippatos ◽  
V. Tsimihodimos ◽  
M. S. Elisaf
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Reduction ◽  
Sglt2 Inhibitors ◽  
Pressure Reduction
Sign in / Sign up

Export Citation Format

Share Document